Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
OncoPharm
00:00
EMERALD Trial Results and Companion Diagnostic
John describes trial design, comparator therapies, companion ESR1 assay, and PFS primary endpoint findings.
Play episode from 08:40
Transcript
